Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Metastatic dissemination is a primary challenge in cancer treatment, particularly in melanoma due to its high metastatic potential.
• Extracellular S100A8/A9 plays a critical role in promoting melanoma distant metastasis, especially to the lungs.
• Melanoma cells are attracted to the lung environment by S100A8/A9, which they can sense via specific receptors.

Purpose of the Study:

• To develop a neutralizing antibody targeting S100A8/A9 to inhibit melanoma lung metastasis.
• To evaluate the efficacy of a novel antibody (Ab45) and its chimeric form in blocking melanoma cell mobility and metastasis.

Main Methods:

• Development of a neutralizing antibody (Ab45) against extracellular S100A8/A9.
• Testing Ab45's ability to suppress S100A8/A9-mediated melanoma cell mobility in vitro.
• Assessment of Ab45 and its chimeric version (chimeric Ab45) in inhibiting lung tropic melanoma metastasis in a mouse model.

Main Results:

• Ab45 demonstrated significant suppression of S100A8/A9-mediated melanoma cell mobility.
• Both Ab45 and chimeric Ab45 effectively inhibited lung tropic melanoma metastasis in vivo.
• The chimeric antibody, composed of mouse Ab45-Fab and human IgG2-Fc, retained inhibitory activity against melanoma metastasis.

Conclusions:

• A novel antibody, Ab45, and its chimeric form show potential in blocking melanoma lung metastasis.
• Targeting the S100A8/A9 pathway with neutralizing antibodies presents a promising therapeutic strategy for melanoma.
• These antibodies could serve as future biological tools in clinical settings to combat melanoma spread.